Ravi Sahu | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Best Researcher Award

Ravi Sahu – Wright State University Boonshoft School of Medicine

Ravi Sahu
Affiliation Wright State University Boonshoft School of Medicine
Country United States
Scopus ID 36833607800
Documents 1076
Citations 1372
h-index 23
Subject Area Pharmacology
Event World Top Scientist Awards
ORCID 0000-0003-3857-9073

Ravi Sahu is a pharmacology researcher associated with Wright State University Boonshoft School of Medicine in the United States. His research profile demonstrates a consistent contribution to biomedical sciences, particularly in cancer pharmacology and molecular therapeutics. The recognition under the Best Researcher Award category reflects scholarly output, citation impact, and involvement in global research collaborations. His work has contributed to advancing understanding in cancer biology, immunotherapy, and drug repurposing strategies [1].

Abstract

This article presents an academic overview of Ravi Sahu, emphasizing his scholarly contributions in pharmacology and cancer research. His work spans experimental therapeutics, immunological pathways, and drug repurposing strategies. The evaluation is based on bibliometric indicators including citation count, h-index, and research output. The profile aligns with international standards used in academic recognition systems [2].

Keywords

Pharmacology, Cancer Research, Immunotherapy, Drug Repurposing, Molecular Biology, Oncology, Research Metrics.

Introduction

The field of pharmacology has evolved significantly with the integration of molecular biology and translational medicine. Researchers such as Ravi Sahu have contributed to bridging laboratory findings with clinical applications. His research focuses on understanding cellular signaling pathways and developing therapeutic interventions. These efforts contribute to improved treatment strategies in oncology [3].

Research Profile

The research profile of Ravi Sahu indicates substantial scholarly output with over a thousand indexed documents and a growing citation base. His work is indexed in major academic databases including Scopus and ORCID. The profile reflects interdisciplinary collaboration and sustained research productivity. These indicators are commonly used to assess academic performance globally [1].

Research Contributions

Ravi Sahu has contributed to multiple areas including cancer therapeutics, platelet-activating factor signaling, and immune checkpoint research. His publications explore mechanisms of tumor progression and therapeutic resistance. The research also includes investigations into repurposed drugs such as metformin and itraconazole. These contributions enhance understanding of treatment optimization strategies [4].

Publications

The publication record includes peer-reviewed journal articles across high-impact biomedical journals. Notable works include studies on lung cancer therapies, melanoma treatment, and molecular signaling pathways. The research demonstrates both experimental and review-based scholarship. These publications contribute to advancing scientific knowledge and clinical practices [5].

Research Impact

The research impact of Ravi Sahu is reflected through citation metrics and academic collaborations. His work has been cited in multiple interdisciplinary studies, indicating relevance across scientific domains. The h-index value highlights consistent scholarly influence. Such metrics are critical in evaluating research visibility and academic significance [2].

Award Suitability

The Best Researcher Award recognizes individuals demonstrating excellence in scientific research and innovation. Ravi Sahu’s academic record meets key criteria including publication output, citation impact, and subject expertise. His involvement in international research initiatives further strengthens his eligibility. These factors collectively support recognition at global scientific platforms [3].

Conclusion

Ravi Sahu’s contributions to pharmacology and cancer research demonstrate sustained academic excellence. His work integrates molecular insights with therapeutic applications, contributing to advancements in biomedical science. The recognition under the Best Researcher Award highlights the significance of his scholarly achievements. Continued research efforts are expected to further enhance his impact in the scientific community [4].

References

  1. Elsevier. (n.d.). Scopus author details: Ravi Sahu, Author ID 36833607800. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=36833607800

  2. Sahu, R. P., Zonfa, C. E., & Thyagarajan, A. (2026). Repurposing itraconazole in combination with chemotherapy and immune checkpoint inhibitor for cancer. Medical Sciences, 14(1), 55.
    https://doi.org/10.3390/medsci14010055

  3. Thyagarajan, A., Gajjar, V., & Sahu, R. P. (2025). Are metformin-based combination approaches beneficial for non-small cell lung cancer: Evidence from experimental and clinical studies. Military Medical Research, 12, 61.
    https://doi.org/10.1186/s40779-025-00649-5

  4. Sahu, R. P., et al. (2025). Platelet-activating factor signaling in cancer. Journal of Applied Toxicology. Advance online publication. https://doi.org/10.1002/jat.4770

  5. Sahu, R. P., et al. (2023). Melatonin in melanoma treatment. Medical Sciences, 11(1), 9.

    https://doi.org/10.3390/medsci11010009

     

Meghraj Suryawanshi | Pharmacology and Pharmaceutical Science | Best Researcher Award

Published on by World Top Scientists

Prof. Dr. Meghraj Suryawanshi | Pharmacology and Pharmaceutical Science | Best Researcher Award

Assistant Professor | Sandip Institute of Pharmaceutical Sciences | India

Dr. Meghraj Vivekanand Suryawanshi is an accomplished Associate Professor and Training & Placement Coordinator at the Sandip Institute of Pharmaceutical Sciences, Nashik, specializing in pharmaceutics. He holds a Ph.D. in Pharmaceutics from Jaipur National University, an M.Pharm in Pharmaceutics from R.C. Patel Institute of Pharmaceutical Education and Research, a B.Pharm from Sinhgad Institutes of Pharmaceutical Sciences, and an MBA in Hospital Administration. Dr. Suryawanshi has extensive professional experience, serving as a Ph.D. research scholar, Assistant Professor at multiple institutions, and co-founder and CTO of AllWell Nutritech LLP, where he contributed to start-up incubation and entrepreneurial initiatives. He has supervised numerous undergraduate and postgraduate students and actively coordinated academic and administrative programs including training and placement, entrepreneurship, library management, and examination coordination. His research focuses on advanced drug delivery systems, formulation development, and pharmaceutical technology, with a significant body of publications contributing to national and international journals. Dr. Suryawanshi has also engaged in editorial responsibilities and professional memberships that support scholarly exchange and innovation in the pharmaceutical sciences. Recognized for his dedication to research, education, and mentorship, he has been instrumental in fostering academic excellence, student development, and industry collaboration, demonstrating leadership, scientific rigor, and a commitment to advancing the field of pharmaceutics at both institutional and broader professional levels.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Suryawanshi, I., Srinidhi, S., Singh, S., Kalia, R., Kunchala, R. K., Mudavath, S. L., …. (2021). Downshifting and upconversion dual mode emission from lanthanide doped GdPO4 nanorods for unclonable anti-counterfeiting. Materials Today Communications, 26, 102144.

2. Patil, S. M., Suryawanshi, M. V., Chandanshive, V. V., Kurade, M. B., Govindwar, S. P., …. (2020). Regeneration of textile wastewater deteriorated microbial diversity of soil microcosm through bioaugmentation. Chemical Engineering Journal, 380, 122533.

3. Suryawanshi, M. V., Gujarathi, P. P., Mulla, T., & Bagban, I. (2024). Hypericum perforatum: A comprehensive review on pharmacognosy, preclinical studies, putative molecular mechanism, and clinical studies in neurodegenerative disorders. Naunyn-Schmiedeberg’s Archives of Pharmacology, 397(6), 3803–3818.

4. Bhagat, D. S., Suryawanshi, I. V., Gurnule, W. B., Sawant, S. S., & Chavan, P. B. (2021). Greener synthesis of CuO nanoparticles for enhanced development of latent fingerprints. Materials Today: Proceedings, 36, 747–750.

5. Suryawanshi, I., Kalia, R., Kunchala, R. K., Mudavath, S. L., & Naidu, B. S. (2022). Detection of latent fingerprints using luminescent Gd0.95Eu0.05PO4 nanorods. Journal of Rare Earths, 40(4), 572–578.

Mantosh Kumar Satapathy | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Dr. Mantosh Kumar Satapathy | Pharmacology | Best Researcher Award

Mantosh Kumar Satapathy  | Taipei Medical University | Taiwan

Dr. Mantosh Kumar Satapathy, Ph.D., is a distinguished biomedical scientist, biotechnologist, pharmacologist, and tissue engineer based at Taipei Medical University, Taiwan, with extensive international experience in pharmacology, biomedical engineering, and nanobiotechnology. He earned his Ph.D. in Biomedical Materials and Tissue Engineering from Taipei Medical University, following an M.Tech. in Industrial Biotechnology and a Bachelor of Pharmacy, establishing a strong foundation in translational medical research. Dr. Satapathy has held postdoctoral and research fellow positions at leading institutions, leading projects on advanced nanodrug delivery systems, stem cell therapeutics, tissue engineering, and nanoformulation design, while supervising molecular biology laboratories and mentoring junior researchers. His research contributions include the development of stimuli-responsive nanocomposite hydrogels for orthopedic and skin tissue regeneration, engineering of nanocurcumin-based formulations for targeted therapies, and investigations into gene regulation and drug repurposing in cancer and skin pathologies. He has published extensively in high-impact peer-reviewed journals, contributed to international book chapters, co-invented a U.S. patent, and presented his work at global scientific conferences. Dr. Satapathy’s work has been recognized with multiple Outstanding Postdoctoral Researcher awards, and he actively serves as a peer reviewer, reflecting his leadership in the scientific community. He is a life member of professional organizations, has completed specialized research training in molecular diagnostics and biotechnology, and continues to advance interdisciplinary research that bridges fundamental science and clinical application, demonstrating exceptional impact in biomedical innovation.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Banerjee, P., Satapathy, M., Mukhopahayay, A., & Das, P. (2014). Leaf extract mediated green synthesis of silver nanoparticles from widely available Indian plants: Synthesis, characterization, antimicrobial property and toxicity analysis. Bioresources and Bioprocessing, 1(1), 3.

2. Satapathy, M. K., Yen, T. L., Jan, J. S., Tang, R. D., Wang, J. Y., Taliyan, R., & Yang, C. H. (2021). Solid lipid nanoparticles (SLNs): An advanced drug delivery system targeting brain through BBB. Pharmaceutics, 13(8), 1183.

3. Satapathy, M. K., & Das, P. (2014). Optimization of crystal violet dye removal using novel soil-silver nanocomposite as nanoadsorbent using response surface methodology. Journal of Environmental Chemical Engineering, 2(1), 708–714.

4. Satapathy, M. K., Banerjee, P., & Das, P. (2015). Plant-mediated synthesis of silver-nanocomposite as novel effective azo dye adsorbent. Applied Nanoscience, 5(1), 1–9.

5. Satapathy, M. K., Nyambat, B., Chiang, C. W., Chen, C. H., Wong, P. C., Ho, P. H., … (2018). A gelatin hydrogel-containing nano-organic PEI–Ppy with a photothermal responsive effect for tissue engineering applications. Molecules, 23(6), 1256.

Laura Machin Galarza | Pharmacology | Young Scientist Award

Published on by World Top Scientists

Assist. Prof. Dr. Laura Machin Galarza | Pharmacology | Young Scientist Award

Laura Machin Galarza | University of Havana | Cuba

Dr. Laura Machin Galarza is an Assistant Professor and Researcher at the Institute of Pharmacy and Foods, University of Havana, specializing in pharmaceutical sciences and parasitology. She holds a Bachelor’s, Master’s, and Doctorate in Pharmaceutical Sciences from the University of Havana, where her academic journey has been marked by excellence and commitment to translational research. Dr. Machin has undertaken prestigious research stays at institutions in Austria, Germany, China, and Cuba, contributing to international collaborations focused on pharmacology, toxicology, and biopharmaceutical innovation. Her professional experience includes leadership in multidisciplinary projects exploring the antiprotozoal and antileishmanial potential of natural and synthetic compounds, advanced drug delivery systems, and pharmacological recycling strategies. She has authored multiple peer-reviewed publications in high-impact journals such as Pharmaceuticals, Molecules, and Experimental Parasitology, demonstrating expertise in medicinal chemistry and drug development. Dr. Machin’s work has been recognized through contributions to award-winning research honored by the Cuban Academy of Sciences. She actively serves in academic editorial processes, participates in professional scientific societies, and holds certifications that reflect her dedication to research excellence, innovation, and scientific leadership in the field of pharmaceutical sciences.

Profiles: Google Scholar | Scopus 

Featured Publications

1. B. Salehi, L. Machin, L. Monzote, J. Sharifi-Rad, S. M. Ezzat, M. A. Salem, et al., “Therapeutic potential of quercetin: new insights and perspectives for human health,” ACS Omega, vol. 5, no. 20, pp. 11849–11872, 2020.

2. B. Tamargo, L. Monzote, A. Piñón, L. Machín, M. García, R. Scull, W. N. Setzer, “In vitro and in vivo evaluation of essential oil from Artemisia absinthium L. formulated in nanocochleates against cutaneous leishmaniasis,” Medicines, vol. 4, no. 2, p. 38, 2017.

3. L. Machín, R. Nápoles, L. Gille, L. Monzote, “Leishmania amazonensis response to artemisinin and derivatives,” Parasitology International, vol. 80, p. 102218, 2021.

4. G. Geroldinger, M. Tonner, J. Quirgst, M. Walter, S. De Sarkar, L. Machín, et al., “Activation of artemisinin and heme degradation in Leishmania tarentolae promastigotes: a possible link,” Biochemical Pharmacology, vol. 173, p. 113737, 2020.

5. L. Machín, B. Tamargo, A. Piñón, R. C. Atíes, R. Scull, W. N. Setzer, L. Monzote, “Bixa orellana L. (Bixaceae) and Dysphania ambrosioides (L.) Mosyakin & Clemants (Amaranthaceae) essential oils formulated in nanocochleates against Leishmania amazonensis,” Molecules, vol. 24, no. 23, p. 4222, 2019.

Ksenia Blinova | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Dr. Ksenia Blinova | Pharmacology | Best Researcher Award

Associate Director at US Food and Drug Administration, United States

Dr. Ksenia Blinova, Ph.D., is the Associate Director for the Division of Applied Regulatory Science at the U.S. Food and Drug Administration, where she leads innovative research, regulatory reviews, and scientific consultations that advance translational science in support of public health. With a strong academic foundation in physics, mathematics, and cardiac electrophysiology, she has built a distinguished career focused on bridging fundamental science with regulatory applications. Since joining the FDA as a Commissioner’s Fellow, Dr. Blinova has held key leadership roles, including Deputy Director of the Division of Biomedical Physics, where she led multidisciplinary teams in developing over forty regulatory science tools that improved the evaluation of medical devices across fields such as cardiology, neurostimulation, diagnostics, and patient monitoring. Her career reflects a unique combination of scientific excellence, leadership, and commitment to advancing safe and effective medical products, making her an influential figure in the field of regulatory science.

Professional Profile 

Scopus Profile | ORCID Profile 

Education

Dr. Ksenia Blinova earned her undergraduate and doctoral degrees in Physics and Mathematics from Moscow State University, where she developed a strong foundation in quantitative sciences and analytical problem-solving. She further advanced her academic journey through a postdoctoral fellowship at the National Heart, Lung, and Blood Institute at the National Institutes of Health. Her research during this period centered on cardiac electrophysiology and metabolism, areas that deepened her expertise in biomedical applications of physical sciences. This educational trajectory not only equipped her with advanced technical knowledge but also gave her a unique interdisciplinary perspective that integrates rigorous physics and mathematical methodologies with life sciences and clinical research. Her educational background has been pivotal in shaping her ability to address complex regulatory and scientific challenges, contributing to her capacity for innovation and leadership in translational science and regulatory policy at the intersection of medicine, technology, and public health.

Experience

Dr. Blinova has built a distinguished career at the U.S. Food and Drug Administration, beginning as a Commissioner’s Fellow and progressing to influential leadership roles. As Deputy Director of the Division of Biomedical Physics in the Center for Devices and Radiological Health, she guided a multidisciplinary team in creating innovative regulatory science tools that addressed critical challenges in medical device safety and effectiveness. Her leadership was instrumental in developing methods and resources for fields such as cardiology, neurostimulation, ophthalmology, in-vivo diagnostics, and advanced patient monitoring. Currently serving as Associate Director for the Division of Applied Regulatory Science in the Office of Clinical Pharmacology, she oversees research, scientific consultations, and regulatory reviews that support the FDA’s translational science priorities. Through these roles, she has combined her technical expertise with strategic vision, ensuring that scientific advancements translate into practical regulatory applications that safeguard patient health and promote medical innovation.

Research Focus

Dr. Blinova’s research focuses on advancing translational and regulatory science to accelerate the safe and effective delivery of medical products to patients. Her early work in cardiac electrophysiology and metabolism provided insights into fundamental mechanisms of heart function, laying the groundwork for her later contributions in biomedical physics and device evaluation. At the FDA, she has led research efforts that integrate computational modeling, experimental studies, and regulatory tool development to address complex safety and efficacy challenges in medical devices and drug-device combinations. Her team has developed innovative approaches to evaluate technologies in cardiology, neurostimulation, electrical safety, diagnostics, and patient monitoring, ensuring that regulatory science keeps pace with rapid technological advances. By bridging basic science, applied research, and policy, her work exemplifies the role of regulatory science in translating innovation into tangible benefits for patients and healthcare systems, while maintaining a focus on safety, effectiveness, and public health impact.

Award and Honor

Throughout her career, Dr. Blinova has been recognized for her leadership, innovation, and contributions to regulatory science. Her accomplishments include guiding the development of over forty regulatory tools that have had a lasting impact on how medical devices are assessed for safety and effectiveness. These achievements reflect not only her scientific expertise but also her ability to collaborate across disciplines to solve pressing healthcare challenges. Her recognition within the FDA and broader scientific community underscores her role as a leader who consistently advances the field of translational science. Honors and awards in her career highlight her success in bridging science and regulation, her dedication to patient safety, and her influence in shaping modern approaches to medical product evaluation. These distinctions serve as a testament to her sustained contributions, her commitment to innovation, and her growing impact as a respected figure in regulatory and biomedical research.

Publication Top Notes

  • Title: Nonclinical Human Cardiac New Approach Methodologies (NAMs) Predict Vanoxerine-Induced Proarrhythmic Potential
    Authors: M. Iveth Garcia, Bhavya Bhardwaj, Keri Dame, Verena Charwat, Brian A. Siemons, Ishan Goswami, Omnia A. Ismaiel, Sabyasachy Mistry, Tromondae K. Feaster, Kevin E. Healy, et al.
    Year: 2025

  • Title: In Vitro Assay Development to Study Pulse Field Ablation Outcome Using Solanum Tuberosum
    Authors: Akshay Narkar, Abouzar Kaboudian, Yasaman Ardeshirpour, Maura Casciola, Tromondae Feaster, Ksenia Blinova
    Year: 2024
    Citations: 2

  • Title: Nonclinical evaluation of chronic cardiac contractility modulation on 3D human engineered cardiac tissues
    Authors: Tromondae K. Feaster, Jourdan K. Ewoldt, Anna Avila, Maura Casciola, Akshay Narkar, Christopher S. Chen, Ksenia Blinova
    Year: 2024

  • Title: Comprehensive Collection of Current Methods for Contractility and Electrophysiology Recordings in Human Cardiac Cells
    Authors: Ksenia Blinova, J. Pierson, A. Narkar
    Year: 2023

  • Title: Human in vitro assay for irreversible electroporation cardiac ablation
    Authors: Maura Casciola, Tromondae K. Feaster, M. J. Caiola, D. Keck, Ksenia Blinova
    Year: 2023

  • Title: Acute effects of cardiac contractility modulation stimulation in conventional 2D and 3D human induced pluripotent stem cell-derived cardiomyocyte models
    Authors: Tromondae K. Feaster, N. Feric, I. Pallotta, A. Narkar, M. Casciola, M. P. Graziano, R. Aschar-Sobbi, Ksenia Blinova
    Year: 2022

  • Title: Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
    Authors: Tromondae K. Feaster, Maura Casciola, Akshay Narkar, Ksenia Blinova
    Year: 2022

  • Title: Human in vitro neurocardiac coculture (iv NCC) assay development for evaluating cardiac contractility modulation
    Authors: Akshay Narkar, Tromondae K. Feaster, Maura Casciola, Ksenia Blinova
    Year: 2022

  • Title: Human cardiomyocytes are more susceptible to irreversible electroporation by pulsed electric field than human esophageal cells
    Authors: Maura Casciola, Devin Keck, Tromondae K. Feaster, Ksenia Blinova
    Year: 2022

  • Title: Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs)
    Authors: Akshay Narkar, James M. Willard, Ksenia Blinova
    Year: 2022

  • Title: Cardiovascular medical devices: Regulatory science research overview in the office of science and engineering laboratories (OSEL) at the food and drug administration (FDA)
    Authors: K. Aycock, Ksenia Blinova, M. Casciola, B. Craven, M. Di Prima, G. D’Souza, N. Duraiswamy, M. Farahmand, P. Hariharan, L. Herbertson, et al.
    Year: 2021

  • Title: Acute effects of cardiac contractility modulation on human induced pluripotent stem cell–derived cardiomyocytes
    Authors: Tromondae K. Feaster, Maura Casciola, Akshay Narkar, Ksenia Blinova
    Year: 2021

Conclusion

Dr. Ksenia Blinova has demonstrated exceptional expertise and leadership in translational and regulatory science, particularly in the evaluation and development of cardiac therapies and medical devices. Her extensive body of research, including numerous high-impact publications on human in vitro cardiac models, contractility modulation, and electroporation assays, reflects a consistent focus on innovative approaches that bridge fundamental science with practical clinical and regulatory applications. She has led multidisciplinary teams to develop tools and methodologies that enhance patient safety, accelerate medical innovation, and provide reliable scientific evidence for regulatory decisions. Her work not only advances the understanding of cardiac electrophysiology and device performance but also sets new standards for predictive, nonclinical cardiac research. Overall, Dr. Blinova’s contributions exemplify the qualities of a pioneering researcher whose scientific rigor, leadership, and commitment to public health make her highly deserving of recognition in any Best Researcher Award.